The Alliance is on a mission to end colorectal cancer. With Project Cure CRC, we’re funding research to make it happen.
Colorectal cancer claims more than 50,000 lives annually in the U.S., with a 13% survival rate for metastatic disease. Despite rising cases in young adults, research funding lags behind, threatening to make CRC the deadliest cancer under 50 by 2030.
Project Cure CRC is making available tens of millions of dollars to innovators whose work aims to expedite colorectal cancer research to a curable science.
Project Cure CRC has already invested millions of dollars into promising high-risk/high-reward research.
Ending colorectal cancer will take broad collaboration. The Alliance seeks supporters and researchers to advance Project Cure CRC.
The U.S. Food and Drug Administration has given researchers at the University of Colorado Anschutz Medical Campus permission to begin a clinical trial of CAR T-cell therapy for people with advanced colorectal cancer who have already tried the standard treatments without lasting success.
A first-of-its-kind trial platform in the colorectal cancer space, Project Cure CRC’s KLEOS is being driven by the Colorectal Cancer Alliance, the leading nonprofit dedicated to ending the disease, in collaboration with GCAR, a pioneer in the design and implementation of innovative clinical trials.
The Colorectal Cancer Alliance will present three poster sessions and deliver an oral presentation at the American Association for Cancer Research Annual Meeting 2026.